[Form 4] enVVeno Medical Corp Insider Trading Activity

Rhea-AI Filing Summary

enVVeno Medical Corp’s chief executive officer and director, Robert A. Berman, reported insider transactions involving both common stock and equity awards. The Form 4 discloses a disposition of 22,236 shares of common stock, and a related filing shows changes in his derivative holdings.

In addition, 200,000 restricted stock units that were granted to him on November 30, 2021 under the company’s Amended and Restated 2016 Omnibus Incentive Plan were voluntarily surrendered and cancelled on December 16, 2025. These units were subject to vesting based on specified performance milestones, which were not achieved, so the unvested awards were given up and no longer provide rights to common shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BERMAN ROBERT ANDREW

(Last) (First) (Middle)

C/O ENVVENO MEDICAL CORPORATION,

70 DOPPLER

(Street)

IRVINE CA 92618

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
enVVeno Medical Corp [ NVNO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								22,236	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	12/16/2025		J			200,000	(1)	11/30/2031	Common Stock	200,000	$0	0	D

Explanation of Responses:

1. The restricted stock units were issued to the Reporting Person on November 30, 2021 pursuant to the Issuer's Amended and Restated 2016 Omnibus Incentive Plan and the Restricted Stock Unit Agreement, subject to vesting upon the achievement of specified performance milestones. The applicable milestones were not achieved, and accordingly, the Reporting Person has agreed to voluntarily surrender and cancel the unvested Restricted Stock Units.

	/s/ Robert A. Berman	12/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did enVVeno Medical Corp (NVNO) report in this Form 4?

The Form 4 reports that Robert A. Berman, the chief executive officer and a director of enVVeno Medical Corp, disposed of 22,236 shares of common stock and updated his derivative (equity award) holdings.

How many restricted stock units did the enVVeno Medical (NVNO) CEO cancel?

Robert A. Berman voluntarily surrendered and cancelled 200,000 restricted stock units that had previously been granted to him under the company’s Amended and Restated 2016 Omnibus Incentive Plan.

Why were the 200,000 restricted stock units for enVVeno Medical (NVNO) cancelled?

The 200,000 restricted stock units were subject to vesting upon achievement of specified performance milestones. According to the disclosure, those milestones were not achieved, and as a result, Berman agreed to surrender and cancel the unvested units.

When were the cancelled restricted stock units at enVVeno Medical originally granted?

The cancelled restricted stock units were issued to Robert A. Berman on November 30, 2021 pursuant to enVVeno Medical Corp’s Amended and Restated 2016 Omnibus Incentive Plan and a Restricted Stock Unit Agreement.

What was the transaction date for the enVVeno Medical (NVNO) CEO’s RSU cancellation?

The Form 4 shows a transaction date of December 16, 2025 associated with the 200,000 restricted stock units that were surrendered and cancelled.

Does the enVVeno Medical (NVNO) Form 4 show any derivative securities remaining after the RSU cancellation?

After the reported transaction involving the 200,000 restricted stock units, the table of derivative securities lists 0 derivative securities beneficially owned by Robert A. Berman.